A mesh back also helps to enhance airflow when the heat is on. A comfy hoodie with a full zip, this Essentials jumper has the classic triple-stripe design that makes Adidas so recognizable ...

We haven’t crunched the numbers, but we’re pretty sure there are at least a zillion options when it comes to sweatshirts. Luckily, the SELF team has tried hundreds of hoodies, crewnecks ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value ...

Whether you favor the hooded, crew, or zip variety, these sustainable hoodies and crewnecks deliver quality and style, and can be paired with everything from a fancy skirt to a matching pair of ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

Novo Nordisk’s CagriSema led to 23% weight loss but missed industry expectations, sending its stock tumbling. The Danish drugmaker released the highly anticipated results of its Phase 3 trial of the ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

Novo Nordisk (NVO) shares crashed on Friday, while its rival Eli Lilly (NYSE:LLY) surged after the Danish drugmaker posted late-stage trial data for its next-gen weight loss therapy, CagriSema.

The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Novo's shares fell as much as 27% after the results were announced ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion ...